BioStock: BioInvent’s CMO comments on the ESMO presentation
BioInvent and Transgene presented promising phase I/IIa data on BT-001 at ESMO in Barcelona this weekend. BioStock contacted BioInvent’s CMO,…
0,617€
-3,59%
Echtzeit-Aktienkurs Transgene S.A.
Bid:
Ask:
Nachrichten zur Transgene S.A. Aktie
BioStock: BioInvent makes a strong entrance at ESMO in Barcelona
BioInvent has released additional positive preliminary efficacy data from its ongoing phase IIa dose expansion study of BI-1808 as a…
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops…
Availability of Transgenes 2023 Universal Registration Document
TRANSGENE (Paris: TNG) today announced that its Universal registration document for the fiscal year ended December 31, 2023, was submitted…
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based…
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
2023 Full-year results and business update …
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
Strasbourg (France), Tokyo (Japan) and Waltham, Mass (USA), March 5th, 2024, 7:30 am CET - Transgene (Euronext Paris: TNG), a…